Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aminoacylase 1 (ACY1) is an enzyme found in many tissues and organs including the kidneys and brain. It catalyzes the hydrolysis of acylated L-amino acids to L-amino acids and an acyl group, playing a key role in the breakdown of proteins by removing acetyl groups from certain amino acids during protein catabolism. This process allows these amino acids to be recycled for new protein synthesis. Mutations in the ACY1 gene cause aminoacylase 1 deficiency—a rare metabolic disorder characterized by neurological symptoms due to impaired removal of acetyl groups from specific amino acids. Reduced or undetectable expression has been observed in some cancers such as small-cell lung cancer. Recent studies have identified circulating levels of this enzyme as a potential biomarker associated with increased risk for developing type 2 diabetes mellitus[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aminoacylase 1 (ACY1).